BACKGROUND Health plans have implemented tiered copayment systems to incentivize members to use less expensive medications However, members need drug price information to make comparisons among therapeutic alternatives Many health plans and pharmacy benefit management companies have implemented online prescription drug price comparison tools to provide such information There has been little published evaluation of these tools OBJECTIVE To evaluate use of an online price comparison tool-MyPharmacyTools (MPT)-by the measures of (a) the extent to which the tool was used, (b) changes in use over the first year after implementation, and (c) the types of members who were most likely to use the tool METHODS Data were provided by a 500 000-member integrated health plan with approximately 156,250 enrolled families The sample included only families with continuous eligibility for all members from July 1, 2006, through June 30, 2008, use of 1 of 7 common copayment structures, and use of the pharmacy benefit in every quarter of the study period Data collected on each member, using pharmacy claims for the time period July 1, 2007, through June 30, 2008, included annual drug costs (total, out-of-pocket, plan-paid, and mail order) and number of unique drugs and unique generic drugs taken during the third quarter of 2007 Data collected also included whether the member had each of several selected chronic diseases (as inferred from drug claims for the third quarter of 2007) and demographics Age, gender, and family size were taken from eligibility files Other demographic data were imputed to members from the demographics of the ZIP code in which they resided MPT was made available to members on July 1, 2007 Use of MPT was measured as the number of times members logged into the site for each quarter during the subsequent year Statistical analyses were conducted at the family rather than at the individual level, and families were defined as users if any family member used MPT at least once during the year Between-group comparisons were evaluated with t-tests, Pearson chi-square tests, and analyses of variance RESULTS Data were analyzed for 8,909 families composed of 28,537 health plan members, of which 464 (5 2%) families used MPT at least once between July 2007 and June 2008 A total of 141 families used MPT in the first quarter it was available, 170 families used it in the second quarter, 185 families in the third quarter, and 182 families during the fourth quarter Users had significantly higher mean [SD] total drug costs ($4,477 [$9,647] vs $2,848 [$3,473], P<0 001) and used significantly more unique drug products (7 7 [5 7] vs 59 [45], P<0 001) and unique generic drug products (5 0 [3 9] vs 3 9 [3 2], P<0 001) than did nonusers Users were significantly more likely than nonusers to use drugs for behavioral diseases (47 0% vs 397%, P=0 002), hypercholesterolemia (358% vs 27 0%, P<0 001), gastric disorders (328% vs 230%, P<0 001), diabetes (183% vs 128%, P<0 001), epilepsy (21 1% vs 106%, P<0 001), cardiovascular problems (483% vs 37 5%, P<0 001), and asthma (140% vs 107%, P=0 025) Families that used MPT were less likely to have a female subscriber than were nonusers (397% vs 490%, P<0 001) Otherwise, users and nonusers Families using MPT in more quarters of the year had higher out-of pocket (P<0 001) and mail order drug costs (P<0 001), took a larger number of drugs (P=0 003) and generic drugs (P=0 019), were more likely to use drugs for diabetes (P=0 049) and cardiovascular disease (P=0 013), and used drugs for a greater number of chronic diseases (P=0 049), compared with less frequent MPT users CONCLUSIONS About 5% of families in a sample from a large integrated health plan used an online prescription drug cost comparison tool during the first year it was available Use increased over the year Users were more likely to have several chronic diseases, took more prescription drugs, and had higher drug costs than nonusers Further, users with more chronic diseases and more prescriptions were more likely to use the tool consistently throughout the year These results indicate that the tool was successful in reaching health plan members who could most benefit from comparative prescription drug price information
